Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention - American Journal of Cardiovascular Drugs
Source : https://link.springer.com/article/10.1007/s40256-023-00594-5
Despite treatment with statins, patients with elevated low-density lipoprotein cholesterol (LDL-C) and triglycerides remain at increased risk for adverse cardiovascular events. Consequently, novel pharmaceutical drugs have been developed to control...
Conclusions/Relevance: The authors are hopeful that the development of new treatment modalities alongside new therapeutic targets will further reduce patients’ risk of adverse cardiovascular events. Apart from statins, data on new drugs’ use in primary cardiovascular prevention remain scarce. For their swift adoption into clinical...
Conclusions: PCSK9 inhibition decreases markers of platelet activation and endothelial dysfunction in ACS patients. PCSK9 is associated with platelets and vascular ECs in LIMA segments and PCSK9 inhibition decreases that interaction.
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control
Learn more about PCSK9 Inhibition and lipid control in this open-access article from ECR Journal. PCSK9 Inhibition: The Big Step Forward in Lipid Control.
Conclusions/Relevance: Thus far, randomised controlled trials have shown that subcutaneous fully human monoclonal antibodies targeting PCSK9, evolocumab and alirocumab, and PCSK9 silencing with inclisiran result in drastic reductions in LDL cholesterol. Additionally, several novel strategies to target PCSK9 are in development, including oral...
Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease: A Review of Current and Emerging Therapies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37464942/
Lipoprotein(a), or Lp(a), is structurally like low-density lipoprotein (LDL) but differs in that it contains glycoprotein apolipoprotein(a) [apo(a)]. Due to its prothrombotic and proinflammatory properties, Lp(a) is an independent risk...
Relevance: The purpose of this review is to describe current recommendations for screening and managing elevated Lp(a), describe the effects of currently available lipid-lowering therapies on Lp(a) levels, and provide insight into emerging therapies targeting Lp(a).
Effect of sodium glucose cotransporter 2 inhibitors on atrial tachy-arrhythmia burden in patients with cardiac implantable electronic devices - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37453072/
Our real world findings suggest that in CIED HF patients, those with SGLT2i had a pronounced reduction in ATA burden and all-cause mortality when compared with those not on SGLT2i.
Conclusion: Our real world findings suggest that in CIED HF patients, those with SGLT2i had a pronounced reduction in ATA burden and all-cause mortality when compared with those not on SGLT2i.